NVO — Clinical Trial Completion for Esperoct® Study
Jun 3, 2027, 4:00:00 AM UTC
Summary
The clinical trial studying Esperoct® (turoctocog alfa pegol) in males with Haemophilia A is expected to complete on June 3, 2027. The study focuses on the long-term treatment effects of Esperoct® during prophylaxis, with 60 participants enrolled. The trial aims to gather data on side effects and treatment efficacy over a period of 5-7 years, depending on participant entry. Participants will continue their usual treatment while providing data on bleeding episodes and treatment responses.
Company
NOVO NORDISK A S (NVO)NYSE — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.novonordisk.comSimilar Events
Expected Trial Completion for AOC 1044 Study
The Phase 2 open-label study of AOC 1044 in Duchenne Muscular Dystrophy is expected to complete on July 31, 2027, assessing long-term safety and efficacy. AOC 1044 is designed to evaluate the treatment's safety, tolerability, pharmacokinetics, and exploratory efficacy in patients with mutations amenable to exon 44 skipping. The trial involves 39 participants receiving intravenous dosing every six weeks over a two-year treatment period, followed by a three-month safety follow-up.
trial completionExpected Trial Completion for Long-Term Follow-Up Study NCT05768269
Century Therapeutics is conducting an observational clinical trial (NCT05768269) to monitor long-term safety, survival, and late adverse events in participants previously treated with its cellular therapy products. The study, which began in April 2024, is expected to complete on March 1, 2040, and will enroll approximately 375 participants. The trial aims to collect persistence data and assess any long-term risks associated with the cellular therapies. This extended follow-up is standard for advanced cell therapy products to ensure comprehensive safety profiling.
trial completionHER2 and LA/mUC Clinical Trial Completion
Seagen Inc., a wholly owned subsidiary of Pfizer, is expected to complete its multi-country chart review cohort study (NCT05902494) on HER2-positive and locally advanced or metastatic urothelial cancer on July 14, 2025. The observational study aims to analyze medical records of 350 patients to better understand the impact of HER2 expression on treatment choices and outcomes in unresectable or metastatic urothelial cancer. The trial is currently recruiting participants.
trial completionExpected Trial Completion for OP-3136 Study in Advanced Solid Tumors
Olema Pharmaceuticals is conducting a Phase 1 clinical trial of OP-3136, an oral KAT6A/B inhibitor, in patients with advanced or metastatic ER+ HER2- breast cancer, castration-resistant prostate cancer, and non-small cell lung cancer. The study, which began in December 2024, aims to assess safety, tolerability, pharmacokinetics, and determine the maximum tolerated dose and recommended regimen. Trial completion is expected on August 30, 2027.
trial completion